血管紧张素受体阻断剂在心血管疾病治疗中的循证研究  

The evidence trials of angiotensinⅡreceptor blockers in the treatment of ardiovascular disease

作　　者：戴秋艳[1] 黄代昵 

机构地区：[1]上海交通大学附属第一人民医院心内科

出　　处：《世界临床药物》2008年第10期577-581,共5页World Clinical Drug

摘　　要：心血管疾病是全世界致死和致残的主要原因,应采取积极措施进行防治。众多大型临床研究都从循证医学方面证明了血管紧张素受体阻断剂(ARB)是一类非常有前途的药物,基于其有效的降压作用及降压之外独特的靶器官保护作用和更少的不良反应,在心血管治疗中可以作为一类强有力阻断肾素-血管紧张素-醛固酮系统(RAAS)的药物,为临床医生增加新的选择。Cardiovascular disease should be intervened actively since it is the key reason for deaths or disablement in all over the world. Many clinical evidence studies have testified that the angiotensin Ⅱ receptor blocker （ARB） is a new kind of ideal medicine based on its antihypertensive effect and target organ protection independent of decreasing hyper- tension as well as no obvious adverse reaction. As a powerful blocker of renin angiotensin aldosterone system （RAAS）, ARB will be the new selection for physicians.

关 键 词：血管紧张素转化酶抑制剂 血管紧张素受体阻断剂 心血管疾病 循证研究 

分 类 号：R972[医药卫生—药品] R54[医药卫生—药学]